CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
15 hedge funds and large institutions have $12.5M invested in CERo Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 32 closing their positions.
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
67% less funds holding
Funds holding: 45 → 15 (-30)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
88% less capital invested
Capital invested by funds: $101M → $12.5M (-$88.6M)
94% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
+$1.64M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$527K |
| 3 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$401K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
-$12.4M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$7.51M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$6.68M |
| 4 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
-$6.27M |
| 5 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$5.57M |
CERO Hedge Fund Activity: Q1 2023 in Review
15 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q1 2023, worth a combined $12.5M — down 88% from $101M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of CERO and 2 opened new positions — a net loss of 30 holders — while 5 trimmed existing stakes and 1 added.
The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $1.64M. The largest seller was Saba Capital Management, exiting entirely with an estimated $12.4M sold.
- 15 institutional investors held CERo Therapeutics (CERO) as of Q1 2023, down from 45 in Q4 2022.
- Funds reported $12.5M of CERo Therapeutics stock for Q1 2023, down 88% quarter-over-quarter.
- 2 funds opened new CERo Therapeutics positions in Q1 2023 and 32 closed out, a net change of -30 holders.
- The largest CERo Therapeutics buyer in Q1 2023 was Cantor Fitzgerald, an estimated $1.64M added.
- The largest CERo Therapeutics seller in Q1 2023 was Saba Capital Management, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2023.